je.st
news
Tag: biologics
Aptimmune Biologics selected by The Yield Lab to participate in Ag Technology Accelerator Program
2016-11-17 20:40:54| National Hog Farmer
Aptimmune Biologics was selected by The Yield Lab, a St. Louis-based agriculture technology business accelerator and investor, to participate in a nine-month program designed to support emerging ag tech companies. Aptimmune Biologics was chosen from among 120 applicants to participate in the program for 2016 and represents The Yield Labs first animal health investment. read more
Tags: technology
program
selected
participate
Green Biologics & HOC Industries Partner to Package & Distribute Renewable Consumer Products
2016-11-02 16:04:00| Coatings World Breaking News
Tags: products
partner
green
package
Green Biologics Unveils High Purity, Bio-Based Product Brands: BioPure & GreenInside
2016-10-12 22:00:00| Coatings World Breaking News
Tags: high
product
green
brands
Green Biologics & Caldic Partner to Bring Renewable Chemicals to EU Market
2016-10-04 07:00:00| Coatings World Breaking News
FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Mercks KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
2016-09-07 12:45:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »